



BRYAN, GARNIER & CO

DAILY EQUITY RESEARCH UPDATE
Wake-up Call

Dow Jones: 24,528.22 (5.15% ytd) | CAC40: 4888.58 (3.34% ytd) | Stoxx 600: 354.381(4.96% ytd)

29th January 2019

Please find our Research on Bloomberg BRYG <GO>

INTERPARFUMS | NEUTRAL | EUR39 vs. EUR37

Healthy EBIT margin in 2018!
FY 2018 sales gained 11% at same FX
Coach drove growth
2018 EBIT margin slightly above 14%
2019 should be a dynamic year in terms of launches
EUR39 FV versus EUR37

GRANDVISION | BUY | EUR26

GrandVision strengthens its omnichannel approach with the acquisition of Charlie Temple
Charlie Temple is a small digital-native brand
Omnichannel approach in Benelux countries
GVNV's 2023 digital target: 10% of total sales from eCommerce

SAP | BUY | EUR121

FY18 profit and FY19 guidance in line, setting ambitions for 2023
FY18 operating profit was in line with expectations
Q4 licence sales were up 8% at cc, driven by America
FY19 guidance in line with consensus, with new restructurings
SAP updates targets for 2020 and sets up ambitions for 2023

BIOCARTIS | Coverage Initiated | report out today

Fully Automated Workflow Driving Double-Digit Growth

Biocartis is a pure-play molecular diagnostic company focused on oncology testing in the clinical setting and positioned on the fast growing EUR6.8bn cancer biomarker testing market (+12% p.a.). The company has developed a fully automated innovative proprietary platform, Idylla, which delivers unmatched time-to-results reducing time to treatment initiation from weeks to 1-2 days. Alongside an improved ease-of-use taking away the human error from the workflow and increasing cost-efficiency for labs, we anticipate a strong adoption of the platform.

Upcoming BG events :

Date	
7th-Mar	AB inBev Genève Roadshow with IR
14th-Mar/	4th Annual Technology Conference
15th-Mar	

Recent reports :

Date	
29th-Jan	BIOCARTIS Fully Automated Workflow Driving Double-Digit Growth
17th-Jan	SemiConductors Favour Infineon, STM, and Soitec in early 2019
9th-Jan	MEDIGENE Targeting Cancer: Therapeutic TCR-T-cells
7th-Dec	Bottlers Canadian Cannabis : Online Retail Survey
6th-Dec	L'OREAL China is L'Oréal's future!
3rd-Dec	HEXO High Demand

Q1 2019 Top Picks

SANOFI (Buy, FV EUR94)
NOVARTIS (Buy, FV CHF100)
GALAPAGOS (Buy, FV EUR125)

INTERPARFUMS

Consumer, Brands & Retail
| HPC

29th January 2019

NEUTRAL

Fair Value EUR39 vs. EUR37 (-9%)
Share price EUR42.85
EPS 3Y Cagr 10.8%

Healthy EBIT margin in 2018!

FY 2018 sales gained 11% at same FX

Interparfums' 2018 sales finally came out at EUR455m, up 8% or 11% at same-FX, whereas the company was still expecting a level of around EUR450m on 15th January and EUR430m in November 2018. Note that this performance was achieved with no major launches and implies an increase of 20% in Q4 alone. By region, 2018 sales were strong in Asia-Pacific (+7%) and in North America (+18% of which +25% at same FX). North America accounts for 30% of total IP 2018 sales. Sales in Western Europe were down a slight 2%, despite a 3% revenue increase in France (in a market down 2%).

Coach drove growth

The main contributor to the 2018 sales increase was the **Coach** brand whose sales reached EUR84m, up 66%, thanks to sharp growth in the US, driven by both the men's and women's lines. Coach accounts for 20% of total 2018 IP sales after only two and a half years of activity. **Jimmy Choo** sales increased 4% to EUR100m, despite demanding comparison with 17% growth in 2017, but thanks to the success of *Jimmy Choo Fever* launched during the summer and *Jimmy Choo Man Blue*. Montblanc revenues were down slightly in 2018 (-3%) due to poor launches last year. Lanvin sales remained almost unchanged in 2018.

2018 EBIT margin slightly above 14%

2018 EBIT margin could exceed 14% whereas 15 days ago, management was expecting profitability between 13.5% and 14% (and 13.5% anticipated last November). The 2018 profitability improvement versus initial expectations was probably driven by gross margin given higher than expected sales, while communication costs were under control as the group had no major launches last year.

2019 should be a dynamic year in terms of launches

This year in Q1, **Montblanc** is due to launch a new line throughout the world (the third one after *Montblanc Legend* and *Montblanc Emblem*) called *Montblanc Explorer*. A second men's line will also be launched at **Jimmy Choo**. **Rochas** is also expected to launch a new women's line in Q4 2019 after *Mademoiselle* (launched in 2017). We expect FY 2019 sales to reach EUR495m (company guidance EUR470m), up 9% with EBIT margin close to 14%.

EUR39 FV versus EUR37

Following higher than expected 2018 sales and 2018 EBIT margin above 14%, we raise our earnings by almost 3%, hence our new Fair Value (EUR39 vs EUR37). We remain at Neutral on the stock.

Market Data

Bloomberg / Reuters	ITP FP/IPAR.PA
Market Cap.	EUR1,841m
E.V.	EUR1.670m
Free Float	27
Avg. Daily volume (6m)	21.10
12m high / low	45.3 / 31.0
Ytd Perf.	27.0%

EURM	12/17	12/18e	12/19e	12/20e
Sales	422.0	455.0	495.0	540.0
% Change		7.8%	8.8%	9.1%
EBITDA	65.0	70.0	75.0	79.0
% Change		7.7%	7.1%	5.3%
EBIT	60.1	65.0	70.0	75.0
% Change		8.2%	7.7%	7.1%
Net Income	40.0	47.0	50.0	54.0
% Change		17.5%	6.4%	8.0%
ROE	0.09	0.10	0.10	0.10

	12/17	12/18e	12/19e	12/20e
EV/Sales	4.0x	3.6x	3.3x	2.9x
EV/EBITDA	25.7x	23.5x	21.5x	20.1x
EV/EBIT	27.8x	25.3x	23.1x	21.2x
EPS	0.92	1.09	1.16	1.26
% change		18.4%	6.4%	8.0%
P/E	46.4x	39.2x	36.9x	34.1x
Div Yield	1.4%	1.5%	1.8%	4.1%

Next Catalyst: Analyst meeting at 9am

Last rating Change:

2018-9-7, Valuation is too demanding!

Last FV Change:

2019-1-15, Higher 2018 sales than expected

Last Reports:

2019-1-15, Higher 2018 sales than expected

Loïc Morvan

33(0) 1 70 36 57 24

lmorvan@bryangarnier.com

[Click here to download](#)

GRANDVISION

Consumer, Brands & Retail
| Optical & Eyewear

29th January 2019

BUY

Fair Value EUR26(+33%)
Share price EUR19.27
EPS 3Y Cagr 7.3%

GrandVision strengthens its omnichannel approach with the acquisition of Charlie Temple

Charlie Temple is a small digital-native brand

Yesterday evening, GNVV announced it had acquired the leading online retailer in Benelux, Charlie Temple, which was only founded in 2016. Although details of the transaction were undisclosed, we estimate that CT generates sales of up to EUR10m. CT belongs to “digital native brands” (DNVB) such as Warby Parker (US), Ace & Tate (NL), Jimmy Fairly (F) or Mr Spex (D) which are starting to disrupt optical retailing and forcing legacy retailers (i.e. optical chains but also independent opticians) to accelerate their digital transformation.

The success of those disruptive eyewear brands relies on:

(i) a vertically-integrated supply chain that enables total control by cutting out intermediaries (i.e. no wholesalers, no royalties contribution) and therefore, offers high-quality products (at Charlie Temple, frames are “Made in Italy” by Mazzuchelli and lenses are by Essilor) at very attractive prices.

(ii) a direct-to-consumer business: with the exception of Mr Spex that is a multi-brand retailer, CT and the other DNVB have a monobrand retail model, i.e. they only sell their products in their own stores (offline and online), which enhances the customer experience.

(iii) a fashion positioning: DNVBs clearly put fashion first (e.g.: CT does not propose eye exams) to stand out from traditional optical retailers and this leads to a proactive marketing strategy on social media

Omnichannel approach in Benelux countries

Note that GNVV is already the No.1 optical retailer in the Netherlands and Belgium (~12% of total sales) with 845 stores. Unlike its Dutch peer Ace & Tate, CT does not run physical stores, nor offer eye exams. Although CT will still operate as an independent brand, we assume eye tests could be proposed in GNVV’s own stores, calling for an enhanced omnichannel experience which proved to be quite successful in Germany and led to significant market share gains vs. Fielmann which is late in its digitalisation strategy.

GNVV’s 2023 digital target: 10% of total sales from eCommerce

As announced at its CMD last September, eCom sales are expected to account for 10% of total revenue by 2023 (vs. 2-3% today), through organic growth and M&A, as highlighted by the acquisition of CT.

We recall that GNVV’s key competitive advantage vs. pure online players is its retail network of 7,000+ stores, which are crucial for the omnichannel implementation, especially since consumers are still reluctant to buy Rx glasses online, considering its current penetration rate of 2-4% (vs. >20% in the fashion industry).

Market Data

Bloomberg / Reuters	GNVV NA/GNVV AS
Market Cap.	EUR4 903
E.V.	EUR5 792
Free Float	22.5
Avg. Daily volume (6m)	87.20
12m high / low	22.8 / 17.9
Ytd Perf.	0.7%

EURm	12/17	12/18	12/19	12/20
Sales	3,450	3,721	3,889	4,075
% Change		7.9%	4.5%	4.8%
EBITDA	551.5	583.6	623.4	666.9
% Change		5.8%	6.8%	7.0%
EBIT	326.8	358.2	402.3	435.9
% Change		9.6%	12.3%	8.4%
Net Income	227.9	228.2	261.5	286.8
% Change		0.1%	14.6%	9.7%
ROE	0.22	0.20	0.20	0.19

	12/17	12/18	12/19	12/20
EV/Sales	1.7x	1.5x	1.4x	1.3x
EV/EBITDA	10.4x	9.6x	8.7x	7.9x
EV/EBIT	17.5x	15.6x	13.5x	12.1x
EPS	0.95	0.95	1.07	1.17
% change		-0.2%	13.3%	9.3%
P/E	20.3x	20.3x	18.0x	16.4x
Div Yield	1.7%	1.7%	1.9%	2.1%

Next Catalyst: FY18 Results on 27th February (before market)

Cédric Rossi

33(0) 1 70 36 57 25
crossi@bryangarnier.com

[Click here to download](#)

SAP

Technology

| Software & IT services

29th January 2019

BUY

Fair Value	EUR121
Share price	EUR92.36
EPS 3Y Cagr	5.6%

FY18 profit and FY19 guidance in line, setting ambitions for 2023

FY18 operating profit was in line with expectations

For FY18, non-IFRS, SAP reported revenues up 11% at cc to EUR24,741m (BG est.: 24,594 or +9.2%; consensus: 24,542; guidance: +7.5%/+8.5%) - o/w Cloud & Software up 10% at cc to EUR20,655m (BG est.: 20,544 or +8.7%; consensus: 20,518; guidance: +8%/+9%), cloud subscriptions up 38% at cc to EUR5,027m (BG est.: 5,004 or +37.8%; consensus: 5,016; guidance: +36.5%/+39%) and licence sales flat at cc to EUR4,647m (BG est.: 4,504; consensus: 4,490) - and operating profit up 6% to EUR7,165m (29% of sales, +0.2ppt) vs. BG est. of EUR7,189m (29.2%) and consensus of EUR7,165bn (29.2%). At cc, non-IFRS op. profit was up 10% at EUR7,480m, or at the mid-point of the guidance (7,425-7,525). Free cash flow was down 25% to EUR2,843m or 12% of sales (vs. 16%). Net debt at end 2018 was EUR2,603m (net gearing: 9%).

Q4 licence sales were up 8% at cc, driven by America

1) at cc, Q4 2018 sales growth was driven by America excluding the US (+52%), the US (+15%) and Japan (+14%); 2) at cc, cloud subscriptions were up 28% for Business Network, up 36% in Public Cloud (SaaS/PaaS), up 47% in Private Cloud (IaaS), and above 100% in Customer Experience; 4) S/4HANA customers reached 10,500 (+1,000 in Q4); 5) Customer Experience posted sales up 50% at cc (>+100% on cloud subscriptions, +14% on licence sales; 6) 35% of the on-premise licence deals were above EUR5m (+5ppt), and this ratio is at 33% for cloud orders (+2ppt); 7) Cloud subscription gross margin was up 1.2ppt to 62.2% (Business Network +1ppt to 78%, SaaS/PaaS +3ppt to 58% including Customer Experience, IaaS +4ppt to 12%).

FY19 guidance in line with consensus, with new restructurings

For 2019, SAP anticipates, non-IFRS and with Qualtrics, revenues up at a rate slightly lower than operating profit, Cloud & Software up 8.5-10% at cc to EUR22.4-22.7bn, Cloud subscriptions up 33-39% at cc to EUR6.7-7bn, and a non-IFRS op. profit up 7.5-11.5% at cc to EUR7.7-8bn. The consensus is for revenues up 8-9% to 26,603 (BG est.: +10.2% at cc to 27,501), Cloud & Software up 9-10% at cc to EUR22,449m (BG est.: +10.7% at cc to 23,065), cloud subscriptions up 31-32% at cc to EUR6,609m (BG est.: +38.8% at cc to 7,066), and a non-IFRS op. profit of 7,905 or 29.7% of sales (BG est.: 8,030 or 29.2%). SAP will implement a restructuring programme with costs estimated at EUR800-950m, the majority of which to be recognised in Q1 2019, with est. EUR750-850m costs savings expected as of 2020 (minor impact in 2019).

SAP updates targets for 2020 and sets up ambitions for 2023

Non-IFRS and with Qualtrics, SAP now expects 2020 revenues of EUR28.6-29.2bn (vs. 28-29 previously), of which EUR8.6-9.1bn (vs. 8.2-8.7) from cloud subscriptions, and EUR8.5-9bn operating profit (unchanged). For 2023, SAP ambitions to post EUR35bn+ revenues (CAGR 2018-2023: 7%+), more than triple cloud subscriptions (CAGR: 25%+), and increase operating by 7.5-10% per annum. Finally, the share of recurring revenues is anticipated to be at 80% (vs. 70-75% for 2020 and 65% in 2018).

Market Data

Bloomberg / Reuters	SAP GR/SAPG.DE
Market Cap.	EUR113,465m
E.V.	EUR114.125m
Free Float	78.8%
Avg. Daily volume (6m)	2 504
12m high / low	107.8 / 82.5
Ytd Perf.	6.2%

EURM	12/17	12/18e	12/19e	12/20e
Sales	23,460	24,549	27,451	30,088
% Change		4.6%	11.8%	9.6%
EBITDA	7,455	7,918	8,895	10,030
% Change		6.2%	12.3%	12.8%
EBIT	6,765	7,138	8,010	9,045
% Change		5.5%	12.2%	12.9%
Net Income	5,655	5,273	5,884	6,665
% Change		-6.8%	11.6%	13.3%
ROE	0.16	0.14	0.15	0.15

	12/17	12/18e	12/19e	12/20e
EV/Sales	4.9x	4.7x	4.3x	3.9x
EV/EBITDA	15.4x	14.5x	13.4x	11.6x
EV/EBIT	17.0x	16.1x	14.9x	12.8x
EPS	4.60	4.29	4.79	5.43
% change		-6.8%	11.6%	13.3%
P/E	20.1x	21.5x	19.3x	17.0x
Div Yield	1.5%	1.6%	1.7%	1.9%

Next Catalyst: Conference call today at 2pm CET (France: +33 1 76 77 22 88; UK: +44 33 03 36 91 26; USA: +1 929 477 04 48).

Last rating Change:

2017-6-19, Avec Leonardo, la croissance a son « joker »

Last FV Change:

2019-1-24, Acquisition of Qualtrics successfully closed

Last Reports:

2019-1-24, Acquisition of Qualtrics successfully closed

Gregory Ramirez

33(0) 1 56 68 75 91

gramirez@bryangarnier.com

[Click here to download](#)

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 54.9%

NEUTRAL ratings 38.5%

SELL ratings 6.6%

Bryan Garnier Research Team

Healthcare	Pharmaceuticals	Eric Le Berrigaud (Head of Equities)	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Pharmaceuticals	Jean-Jacques Le Fur, PharmD	33(0) 1 70 36 57 45	jjlefur@bryangarnier.com
	Biotech	Gary Waanders	44 207 332 25 45	gwaanders@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
	Biotech/Medtech	Victor Floc'h	33 (0) 1 70 36 57 01	vfloch@bryangarnier.com
Technology	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecoms & Media	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductors	Frédéric Yoboué	33 (0) 1 56 68 75 64	fyoboue@bryangarnier.com
Consumer, Brands & Retail	Beverages & Cannabis	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retail & e-commerce	Clément Genelot	33 (0) 1 56 68 75 60	cgenelot@bryangarnier.com
	Luxury/Cosmetics	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	HPC & e-commerce	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
Smart Industries	Insurance	Olivier Pauchaut (Head of Research)	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
	Utilities & Renewables	Pierre-Antoine Chazal	33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
	Lodging & Business services	Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
	Construction & Building materials	Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Corporate Event Manager		Julie Montel	33(0) 1 56 68 75 46	jmontel@bryangarnier.com
Market Data & Information Systems Manager		Eric Monnier	33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	Munich	Zurich	New York
Bryan, Garnier & Co Ltd	Bryan, Garnier & Co Ltd	Bryan, Garnier & Co. GmbH	Bryan, Garnier & Co	Bryan Garnier Securities
Beaufort House	26 Avenue des Champs-Élysées	Widenmayerstrasse 29	Theaterstrasse 4	750 Lexington Avenue
15 St. Botolph Street	75008 Paris	80538 Munich	8001 Zurich	16th floor
London EC3A 7BB	France	Germany	Switzerland	New York, NY 10022
United Kingdom				United States
+44 207 332 2500	+33 1 56 68 75 20	+49 89 2422 62 11	+41 44 991 3300	+1 212 337 7000

IMPORTANT INFORMATION

This document is classified under the FCA Handbook as being investment research (independent research). Bryan, Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan, Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan, Garnier & Co Limited is authorized and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom.

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom This Report has not been approved by Bryan, Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan, Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

This Report is based on information obtained from sources that Bryan, Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan, Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its

accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan, Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.